Please Note: Microsoft has ended support of its older browsers as of January 2016. If you are seeing this message, you are viewing the site on an unsupported version of Internet Explorer (IE10 or older). To properly view this website, please upgrade your version of IE or access this site using a different browser. Thank you.
Sign InDues Join Privacy Contact Search
Home News Scrip

Scrip

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below.

John Lezcano
Corporate Account Manager
M: (631) 807-4971
John.lezcano@informa.com

Pharma intelligence | informa
P: (212) 652-2678
pharmaintelligence.informa.com

Scrip
Tuesday, September 29, 2020
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with...
Tuesday, September 29, 2020
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant...
Tuesday, September 29, 2020
A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert...
Tuesday, September 29, 2020
With digital marketing initiatives becoming key to communication with health providers, COVID-19 has presented the perfect storm to place customers...
Tuesday, September 29, 2020
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's...
Tuesday, September 29, 2020
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under...
Monday, September 28, 2020
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m...
Monday, September 28, 2020
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and...
Monday, September 28, 2020
Monday, September 28, 2020
Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening...